Compounds > abyssinone v
Page last updated: 2024-11-07

abyssinone v

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

abyssinone V: isolated from Erythrina sigboidea; RN from Chemical Abstracts Index Guide; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

abyssinone V : A trihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5, 7 and 4' and prenyl groups at positions 3' and 5' respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
ErythrinagenusA genus of leguminous shrubs or trees, mainly tropical, yielding useful compounds such as ALKALOIDS and PLANT LECTINS.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID442153
CHEMBL ID255890
CHEBI ID2368
MeSH IDM0158936

Synonyms (22)

Synonym
(2s)-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]chroman-4-one
5,7-dihydroxy-2-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-2,3-dihydro-4h-chromen-4-one
4h-1-benzopyran-4-one, {2,3-dihydro-5,7-dihydroxy-2-[4-hydroxy-3,} 5-bis(3-methyl-2-butenyl)phenyl]-, (s)-
CHEBI:2368 ,
abyssinone-v
(2s)-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-en-1-yl)phenyl]-2,3-dihydro-4h-chromen-4-one
ACON1_000328
MEGXP0_000009
ACON0_000344
C09319
abyssinone v
NCGC00169181-01
LMPK12140275
bdbm50241416
CHEMBL255890 ,
(2s)-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]-2,3-dihydrochromen-4-one
4h-1-benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-[4-hydroxy-3,5-bis(3-methyl-2-buten-1-yl)phenyl]-,(2s)-
AKOS030553562
Q27105643
DTXSID001318016
CS-0142140
HY-N8265
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
trihydroxyflavanoneA hydroxyflavanone carrying three hydroxy substituents.
4'-hydroxyflavanonesAny hydroxyflavanone having a hydroxy substituent located at position 4'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)31.15000.00053.49849.7600AID379219; AID612168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID379219Inhibition of human recombinant PTP1B2006Journal of natural products, Nov, Volume: 69, Issue:11
Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii.
AID359674Antimicrobial activity against Candida utilis ATCC 42402 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID359673Antimicrobial activity against Mucor mucedo IFO 7684 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID1455931Cytotoxicity against human MDA-MB-231 cells2017Journal of natural products, 02-24, Volume: 80, Issue:2
Flavonoids from Erythrina schliebenii.
AID359675Antimicrobial activity against Saccharomyces cerevisiae IFO 0203 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID359677Antimicrobial activity against Escherichia coli IFO 3545 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID359672Antimicrobial activity against Penicillium crustosum Thom after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID580925Cytotoxicity in human PC3M cells assessed as inhibition of cell proliferation after 3 days by MTT assay2010ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression.
AID327475Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by microculture radioisotope assay2008Journal of natural products, Jan, Volume: 71, Issue:1
Erythrina alkaloids and a pterocarpan from the bark of Erythrina subumbrans.
AID580924Cytotoxicity in human PC3M cells assessed as inhibition of cell proliferation upto 50 uM after 3 days by MTT assay2010ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8
Concise syntheses of the abyssinones and discovery of new inhibitors of prostate cancer and MMP-2 expression.
AID1455930Antimycobacterial activity against Mycobacterium tuberculosis H37Rv2017Journal of natural products, 02-24, Volume: 80, Issue:2
Flavonoids from Erythrina schliebenii.
AID327476Antimycobacterial activity against Mycobacterium tuberculosis H37Ra by Alamar blue assay2008Journal of natural products, Jan, Volume: 71, Issue:1
Erythrina alkaloids and a pterocarpan from the bark of Erythrina subumbrans.
AID612168Inhibition of human recombinant PTP1B assessed as p-nitorphenol production after 30 mins2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
New 5-deoxyflavonoids and their inhibitory effects on protein tyrosine phosphatase 1B (PTP1B) activity.
AID385354Cytotoxicity against rat H4IIE cells after 24 hrs by MTT assay2008Journal of natural products, Apr, Volume: 71, Issue:4
Prenylated flavonoid derivatives from the bark of Erythrina addisoniae.
AID359678Antimicrobial activity against Bacillus subtilis ATCC 6633 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID359676Antimicrobial activity against Pseudomonas aeruginosa IAM 1007 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
AID359679Antimicrobial activity against Staphylococcus aureus NCTC 8530 after 2 days by twofold serial broth dilution method1993Journal of natural products, Sep, Volume: 56, Issue:9
Ethnobotanical drug discovery based on medicine men's trials in the African savanna: screening of east African plants for antimicrobial activity II.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1510carbohydrazideantitubercular agent;
drug allergen
ursolic acid
[no description available]		2.4520hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
warburganal
[no description available]		1.9810tertiary alcohol
polygodial
[no description available]		1.9810aldehyde
4',5,6,7-tetramethoxyflavone
4',5,6,7-tetramethoxyflavone: structure given in first source; from plant Eupatorium odoratum. 4',5,6,7-tetramethoxyflavone : A tetramethoxyflavone that is the tetra-O-methyl derivative of scutellarein.		2.1510tetramethoxyflavoneantimutagen;
plant metabolite
liquiritigenin
liquiritigenin: structure given in first source; isolated from Pterocarpus marsupium. 4',7-dihydroxyflavanone : A dihydroxyflavanone in which the two hydroxy substituents are located at positions 4' and 7.. liquiritigenin : A dihydroxyflavanone compound having the two hydroxy substituents at the 4'- and 7-positions. Isolated from the root of Glycyrrhizae uralensis, it is a selective agonist for oestrogen receptor beta.		2.73304',7-dihydroxyflavanonehormone agonist;
plant metabolite
phaseollidin
phaseollidin: from Erythrina burana; RN refers to (6aR-cis)-isomer; structure given in first source. phaseollidin : A member of the class of pterocarpans that is (6aR,11aR)-pterocarpan substituted by hydroxy groups at positions 3 and 9 and a prenyl group at position 10.		1.9810pterocarpans
cristacarpin
cristacarpin: isolated from Erythrina burana; RN given refers to (6aS-cis)-isomer; structure given in first source		1.9810pterocarpans
sinensetin
sinensetin: isolated from citrus fruit; exhibit antiadhesive action on platelets. sinensetin : A pentamethoxyflavone that is flavone substituted by methoxy groups at positions 5, 6, 7, 3' and 4' respectively.		2.1510pentamethoxyflavoneplant metabolite
isosakuranetin
isosakuranetin: structure in first source. 4'-methoxy-5,7-dihydroxyflavanone : A dihydroxyflavanone that is flavanone substituted by hydroxy groups at positions 5 and 7 and a methoxy group at position 4' (the 2S stereoisomer).		2.0410(2S)-flavan-4-one;
4'-methoxyflavanones;
dihydroxyflavanone;
monomethoxyflavanone		plant metabolite
lupeol
[no description available]		2.1510pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		2.0410(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
abyssinone i
abyssinone I: anti-oxidant and cytotoxic compound from East African medicinal plant Erythrina abyssinica; structure in first source. abyssinone I : A monohydroxyflavanone that is (2S)-2',2'-dimethyl-2,3-dihydro-2'H,4H-2,6'-bichromen-4-one carrying a hydroxy substituent at position 7.		2.4120monohydroxyflavanone;
phenols		apoptosis inhibitor;
plant metabolite
cinnamodial
cinnamodial: dialdehyde sesquiterpene; structure in first source		1.9810tertiary alcohol
naringin
[no description available]		2.0310(2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside		anti-inflammatory agent;
antineoplastic agent;
metabolite
Euchrestaflavanone A
[no description available]		2.0410flavanones
isoliquiritigenin
[no description available]		2.0310chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
alpinumisoflavone
alpinumisoflavone: extract from twigs of poisonous British plant		3.940isoflavanonesmetabolite
abyssinone ii
abyssinone II: chemopreventive agent from Broussonetia papypera; structure in first source		2.0510
1-methoxyerythrabyssin ii
1-methoxyerythrabyssin II: from the bark of Erythrina subumbrans; structure in first source		2.0410
rk 682
[no description available]		2.0310
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.1510cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Biliary Calculi
[description not available]		03.0310
Gallstones
Solid crystalline precipitates in the BILIARY TRACT, usually formed in the GALLBLADDER, resulting in the condition of CHOLELITHIASIS. Gallstones, derived from the BILE, consist mainly of calcium, cholesterol, or bilirubin.		03.0310